Evidence map›Paper›PMID 31970686›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2020

Cyclooxygenase-2 expression as a prognostic factor in pediatric classical Hodgkin lymphoma.

Y Elborai, A Elgammal, A Salama, M Fawzy, E D El-Desouky, I Attia, L M Shalaby

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Y ElboraiPediatric Oncology Department, National Cancer Institute (NCI), Cairo University, Fom El-khalig Square Kasr El-Aini St., Cairo, 11796, Egypt. yasser.elborai@cu.edu.eg.ORCID http://orcid.org/0000-0002-5528-0025
A ElgammalPediatric Oncology Department, National Cancer Institute (NCI), Cairo University, Fom El-khalig Square Kasr El-Aini St., Cairo, 11796, Egypt.
A SalamaPathology Department, National Cancer Institute (NCI), Cairo University, Cairo, Egypt.
M FawzyPediatric Oncology Department, National Cancer Institute (NCI), Cairo University, Fom El-khalig Square Kasr El-Aini St., Cairo, 11796, Egypt.
E D El-DesoukyBiostatistics and Cancer Epidemiology Department, National Cancer Institute (NCI), Cairo University, Cairo, Egypt.
I AttiaPediatric Oncology Department, National Cancer Institute (NCI), Cairo University, Fom El-khalig Square Kasr El-Aini St., Cairo, 11796, Egypt.
L M ShalabyPediatric Oncology Department, National Cancer Institute (NCI), Cairo University, Fom El-khalig Square Kasr El-Aini St., Cairo, 11796, Egypt.
Cairo University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeCyclooxygenase-2 (COX-2) is an inflammation-related enzyme that has been shown to have a role in tumor initiation, angiogenesis, and proliferation. It has been demonstrated that COX-2 expression is increased in many tumors and is a negative prognostic parameter. Our objective is to investigate the prognostic value of COX-2 expression in pediatric patients with classical Hodgkin lymphoma (CHL).

methodsThis was a retrospective analysis in pediatric patients (n = 127) diagnosed with CHL and treated at the pediatric oncology department, National Cancer Institute, Cairo University, January 2005-June 2013. We correlated COX-2 immunostaining in Reed-Sternberg (RS) cells with clinical variables and outcome.

resultsCOX-2 was expressed on 38.6% of RS cells. The median follow-up time was 48.4 months (range 4-114 months). The 5-year OS and PFS, in COX-2(+ve) versus COX-2(-ve) was 85.3% versus 96.0% (p = 0.248) and 78.6% versus 84.3% (p = 0.354), respectively. A multivariate analysis showed that COX-2(+ve) was not significantly associated with the 5-year OS (HR = 2.9; 95% CI 0.7-12.4, p = 0.149) or with the 5-year PFS (HR = 1.4; 95% CI 0.6-3.2, p = 0.490). High-risk patients in the COX-2(+ve) group had a significantly lower 5-year OS (p = 0.021). The 5-year PFS was significantly lower in the COX-2(+ve) group with B symptoms (p = 0.023) and bulky disease (p = 0.028). Radiotherapy was given only to high-risk patients; survival was much better in radiation-treated children in both the Cox-2(+ve) and Cox-2(-ve) groups. The magnitude of the radiotherapy effect was also greater in the Cox-2(+ve) group, but this difference was not statistically significant.

conclusionCOX-2 expression showed a tendency to be a poor prognostic factor, but it failed to provide meaningful independent information. Further larger studies are needed to investigate COX-2 as a prognostic factor and potential therapeutic target.

Indexed as

AdolescentAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorChildChild, PreschoolCyclooxygenase 2FemaleFollow-Up StudiesHodgkin DiseaseHumansMalePrognosisRetrospective StudiesSurvival RateBiomarkers, TumorCyclooxygenase 2PTGS2 protein, humanClassical Hodgkin lymphomaCOX-2PediatricPrognostic factorRadiotherapy

Identifiers

PMID31970686
OpenAlexW3001881966

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.